Atherosclerotic plaques of cholesterol mainly from LDL, LDL-C can be used as evaluation of the prognosis of patients with stable angina objective material indicators.

动脉粥样硬化斑块中的胆固醇主要来自LDL, LDL - C可以作为评价稳定型心绞痛患者预后的客观物质指标。

youdao

KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

In December 2012, the FDA approved Juxtapid (lomitapide) to reduce LDL-C, total cholesterol, apolipoprotein B, and non HDL-C in patients with HoFH.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia